Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply We thank Golombek and Sola for their comments on our article.1 We completely agree with their concern regarding diuretics and particularly increased synthesis of prostaglandin following administration of furosemide2 (and not prostaglandin inhibition as mentioned in the letter). We would like to inform the readers that Figure 1 of the article1 was shown to inform readers of all therapeutic modalities used so far in the treatment of patent ductus arteriosus. In the text, it is clearly written “However, 3 RCTs [randomized clinical trials] of furosemide showed no apparent benefit,” and at no point in the article did we assert that diuretics should be used for the treatment of patent ductus arteriosus. We would like to point out that in addition to its potential for increasing ductal size, furosemide is also associated with nephrotoxic effects, and it is not recommended for the treatment of patent ductus arteriosus.3,4
Shah PS, Jain A. Patent Ductus Arteriosus in Preterm Neonates—Concerns With Some Recommendations. JAMA Pediatr. 2015;169(12):1177-1178. doi:10.1001/jamapediatrics.2015.2792